Pathogen-Specific Non-Coding RNA Biomarkers for Microbial Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic and therapeutic methods for microbial infections are complex, time-consuming, and often result in false positives or negatives, making it difficult to effectively treat intracellular microbial infections due to challenges in delivering antibiotics and antibodies to infected cells.
Innovation Solution
The use of non-coding RNAs (ncRNAs) specific to in vivo pathogens, which can serve as biomarkers for detection and therapeutic targets, allowing for the development of simpler and more accurate diagnostic methods and treatments by inhibiting pathogen-specific ncRNAs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional diagnostic methods (bacteriological diagnosis, antibody detection, gene diagnosis) are used to detect microbial infections, then detection can be performed, but the operations are tedious, require strict conditions, take long time, and produce high false positive rates
Solution Approach 1:
The patent extracts and utilizes specific microRNA sequences (such as hsa-miR-122-5p, hsa-miR-155-5p, hsa-miR-21-5p) that are selectively expressed during microbial infections as diagnostic markers. By focusing on these specific molecular biomarkers rather than performing comprehensive bacteriological or gene diagnosis, the detection method achieves high accuracy while simplifying the diagnostic process and reducing false positives
Solution Approach 2:
The patent employs microRNA sequences as intermediary biomarkers that mediate between the microbial infection state and the diagnostic detection system. These microRNAs serve as reliable indicators that can be detected through simplified methods (such as qRT-PCR or microarray analysis) without requiring complex culturing or antibody-based assays, thereby achieving accurate detection with reduced operational complexity
2Reliability
If antibiotics and antibodies are delivered to treat intracellular microbial infections, then therapeutic intervention can be attempted, but it is difficult to deliver these agents to infected cells and achieve effective microbicidal effect
Solution Approach 1:
The patent extracts and targets specific microRNA sequences that are selectively expressed by or in response to intracellular microbes. By designing inhibitors or antisense oligonucleotides complementary to these specific microRNA sequences, the therapy can specifically interfere with microbial survival or host cell processes that the microbes exploit, achieving effective treatment without needing to physically deliver antibiotics or antibodies into the infected cells
Solution Approach 2:
The patent replaces the mechanical/physical approach of delivering antibiotics and antibodies into cells with a molecular-level intervention using microRNA-targeted inhibitors. Instead of attempting to overcome cellular barriers through physical delivery methods, the therapy uses sequence-specific molecular recognition and interference at the RNA level, thereby achieving therapeutic effect without the delivery challenges associated with conventional agents
Data Source
Figure 1~3
Figure 4~5
Figure 6A~6D
AI summary
Provided is non-coded RNA of in-vivo infected microorganisms, parasitic microorganisms, symbiotic microorganisms and identification and application thereof. Also provided is a method of identifying the non-coded RNA of in-vivo pathogen sources.